检索结果-南通市图书馆

Syntactic Cate.orization in Fre.ch-Le.rning Infants

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Syntactic Categorization in French-Learning Infants

8-Hydroxyquinolylnitrone. as multifunctional ligands for the.the.apy of ne.rode.e.e.ative.dise.se.

作者： Rushe. Shi Andréane Me.an?on départe.e.t de.Psychologie.Unive.sité du Québe. à Montréal

Re.e.t work showe. that infants re.ognize.and store.function words starting from the.age.of 6–8 months. Using a visual fixation proce.ure. the.pre.e.t study te.te. whe.he. Fre.ch-le.rning 14-month-olds have.the.knowle.ge.of syntactic cate.orie. of de.e.mine.s and pronouns, re.pe.tive.y, and whe.he. the. can use.the.e.function words for cate.orizing nove. words to nouns and ve.bs. The.prosodic characte.istics of nove. words stimuli for noun ve.sus ve.b use. we.e.balance.. The.only distinguishing cue.was the.pre.e.ing de.e.mine.s ve.sus subje.t pronouns, the.forme. be.ng the.most common for nouns and the.latte. the.most common for ve.bs, i.e., de. + Noun, Pron + Ve.b. We.e.pe.te. that noun cate.orization may be.e.sie. than ve.b cate.orization be.ause.the.co-occurre.ce.of de.e.mine.s with nouns is more.consiste.t than that of subje.t pronouns with ve.bs in Fre.ch. The.re.ults showe. that infants groupe. the.individual de.e.mine.s as one.common class, and that the. appe.re. to use.the.de.e.mine.s to cate.orize.nove. words into ***, we.found no e.ide.ce.of ve.b cate.orization. Unlike.de.e.mine.s,pronouns we.e.not pe.ce.ve. as a common syntactic class.

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Acta Pharmace.tica Sinica B 2023年第5期13卷 2152-2175页

作者： damijan Kne. danie. die.-Irie.a Mourad Chioua Andre. Gottinge. Milica de.ic Fabie. Chante.re.l Florian Nachon Xavie. Brazzolotto Anna Skrzypczak-Wie.cioch ane Me.e. Anja Pilar Janko Kos Simon ake.j Jure.Stojan Kinga Saat Julia Se.rano Ana Patricia Fe.nánde. Aitana Sánche.-García Ricardo Martíne.-Murillo Claudia Binda Francisco Lópe.-Muoz Stanislav Gobe. JoséMarco-Conte.le. Unive.sity of Ljubljana Faculty of PharmacyLjubljana 1000Slovenia Laboratory of Me.icinal Che.istry(Institute.of Organic Che.istry CSIC)Madrid 28006Spain de.artame.to de.Química Orgánicay Química Inorgánica Alcaláde HenaresMadrid 28871Spain de.artme.t of Biology and Biote.hnology University of PaviaPavia 27100Italy départe.e.t de.Toxicologie.e. Risque. Chimique. Institut de Recherche Biomédicale des ArméesParis 91220France de.artme.t of Animal Anatomy and Pre.linical Scie.ce. University Centre of Veterinary Medicine JU-UAUniversity of Agriculture in KrakowKrakow 30-059Poland Institute.of Bioche.istry Faculty of MedicineUniversity of LjubljanaLjubljana 1000Slovenia de.artme.t of Pharmacodynamics Chair of PharmacodynamicsFaculty of PharmacyJagiellonian University Medical CollegeKrakow 30-688Poland de.artme.t of Translational Ne.robiology Neurovascular Research GroupCajal Institute(CSIC)Madrid 28002Spain Biote.hnology and Ve.e.al Biology de.artme.t Escuela Técnica Superior de Ingeniería AgronómicaAlimentaria y de BiosistemasUniversidad Politécnica de MadridMadrid 28040Spain Faculty of He.lth Camilo JoséCela University of Madrid(UCJC)Neuropsychopharmacology Unit“Hospital 12 de Octubre”Research InstituteMadrid 28692Spain

We.de.cribe.the.de.e.opme.t of quinolylnitrone.(QNs)as multifunctional ligands inhibiting choline.te.ase.(Che.:ace.ylcholine.te.ase.and butyrylcholine.te.ase.h BChe.and monoamine.oxidase.(hMAO-A/B)for the.the.apy of ne.rode.e.e.ative.*** ide.tifie. QN 19,a simple.low mole.ular we.ght nitrone.that is re.dily synthe.ize. from comme.cially available.*** 19 has no typical pharmacophoric e.e.e.t to sugge.t Che.or MAO inhibition,ye. une.pe.te.ly showe. pote.t inhibition of h BChe.IC50=1.06±0.31 nmol/L)and h MAO-B(IC_(50)=4.46±0.18μmol/L).The.crystal structure. of 19 with hBChe.and hMAO-B provide. the.structural basis for pote.t binding,which was furthe. studie. by e.zyme.*** 19 acte. as a fre. radical scave.ge. and biome.al che.ator,crosse. the.blood—brain barrie.,was not cytotoxic,and showe. ne.roprote.tive.prope.tie. in a 6-hydroxydopamine.ce.l mode. of Parkinson's *** addition,in vivo studie. showe. the.anti-amne.ic e.fe.t of 19 in the.scopolamine.induce. mouse.mode. of Ad without adve.se.e.fe.ts on motoric function and ***,chronic tre.tme.t of double.transge.ic APPswe.PS1δe. mice.with 19 re.uce. amyloid plaque.load in the.hippocampus and corte. of fe.ale.mice.unde.scoring the.dise.se.modifying e.fe.t of QN 19.

关键词： Quinolylnitrone Butyrylcholine.te.ase Monoamine.oxidase.B Alzhe.me.'s dise.se Multifunctional ligands 6-Hydroxydopamine.mode. Passive.avoidance.task Nove. obje.t re.ognition

倾斜台实验诊断血管迷走神经性晕厥——心功能诊断的新方法

在线全文

学校读者我要写书评

暂无评论

德国医学 2000年第1期17卷 38-40页

作者： Martin H.Hust Karl F.heck Matthias W.Ke.m 宋玉娥 Me.izinische.Klinik Kre.skranke.haus Re.tlinge. Ste.ne.be.gstraβe.31 d-72764 Reutlingen Germany 同济医科大学附属同济医院

晕厥是指突发的、短暂的意识和肌张力障碍。多为收缩压降低(在70mmHg 以下)使脑血流量减少所致。患者晕厥前期常有恶心、面色苍白、眩晕、上腹部不适、视物模糊等症状。据统计,约20%～30%的人在其一生中至少发生过一次晕厥。其中以年青... 详细信息

晕厥是指突发的、短暂的意识和肌张力障碍。多为收缩压降低(在70mmHg 以下)使脑血流量减少所致。患者晕厥前期常有恶心、面色苍白、眩晕、上腹部不适、视物模糊等症状。据统计,约20%～30%的人在其一生中至少发生过一次晕厥。其中以年青人或运动员常见。而大多数晕厥患者常很难找到病因。血管神经性晕厥最常见。以往主要通过详细询问病史。

关键词：晕厥血管迷走神经性倾斜台实验

卒中和短暂性脑缺血发作患者的卒中预防指南（续前）美国心脏协会／美国卒中协会为医疗卫生专业人员制定的指南

在线全文

学校读者我要写书评

暂无评论

国际脑血管病杂志 2014年第12期22卷 881-901页

作者：洪道俊黄招君李小兵周美鸿吴成斯王博卢艺吴裕臣 Walte. N. Ke.nan Bruce.Ovbiage.e.He.ry R. Black dawn M. Bravata Marc I. Chimowitz Michae. d. e.e.owitz Margare. C. Fang Marc Fishe. Kare. L. Furie.donald V. heck S. Claiborne.(Clay) Johnston Scott e. Kasne. Ste.e. J. Kittne. Pame.a H. Mitche.l 2. .. Michae. wl Rich de.uran .Nchardson Le. H. Schwamm John A. Wilson 南昌大学第一附属医院神经内科 330006 代表美国心脏协会卒中委员会、心血管和卒中护理委员会、临床心脏病学委员会以及周围血管病委员会

5非心源性栓塞性卒中或TIA的抗栓治疗5．1抗血小板药FdA已批准4种抗血小板药用于预防卒中或TIA患者的血管事件：阿司匹林、阿司匹林／双嘧达莫联合应用、氯吡格雷和噻氯匹定。平均而言，这些药物能使卒中、MI或死亡的船降低22％，但这... 详细信息

5非心源性栓塞性卒中或TIA的抗栓治疗5．1抗血小板药FdA已批准4种抗血小板药用于预防卒中或TIA患者的血管事件：阿司匹林、阿司匹林／双嘧达莫联合应用、氯吡格雷和噻氯匹定。平均而言，这些药物能使卒中、MI或死亡的船降低22％，但这些药物之间存在重要的差异，这会直接影响治疗的选择。

关键词： TIA患者卒中协会美国心脏协会短暂性脑缺血发作卫生专业人员预防非心源性栓塞性卒中指南

卒中和短暂性脑缺血发作患者的卒中预防指南(续前)

在线全文

学校读者我要写书评

暂无评论

国际脑血管病杂志 2014年第12期22卷 881-901页

作者： Ke.nan Walte. N. Ovbiage.e.Bruce.Black He.ry R. Bravata dawn M. Chimowitz Marc I. e.e.owitz Michae. d. Fang Margare. C. Fishe. Marc Furie.Kare. L. heck donald V. Johnston S. Claiborne.(Clay) Kasne. Scott e. Kittne. Ste.e. J. Mitche.l Pame.a H. Rich Michae. W. Richardson de.uran Schwamm Le. H. Wilson John A. 洪道俊(译者) 黄招君(译者) 李小兵(译者) 周美鸿(译者) 吴成斯(译者) 王博(译者) 卢艺(译者) 吴裕臣(译者) 代表美国心脏协会卒中委员会、心血管和卒中护理委员会、临床心脏病学委员会以及周围血管病委员会南昌大学第一附属医院神经内科 330006

Passive.te.hnologie. for future.large.scale.photonic inte.rate. circuits on silicon: polarization handling, light non-re.iprocity and loss re.uction

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Light(Scie.ce.& Applications) 2012年第1期1卷 134-145页

作者： daoxin dai Jare. Baute.s John e.Bowe.s de.artme.t of e.e.trical and Compute. e.gine.ring University of CaliforniaSanta BarbaraCA 93106USA Ce.tre.for Optical and e.e.tromagne.ic Re.e.rch State Key Laboratory for Modern Optical InstrumentationZhejiang UniversityZijingangHangzhou 310058China

Silicon-base. large.scale.photonic inte.rate. circuits are.be.oming important,due.to the.ne.d for highe. comple.ity and lowe. cost for optical transmitte.s,re.e.ve.s and optical *** this pape.,passive.te.hnologie. for large.scale.photonic inte.rate. circuits are.de.cribe.,including polarization handling,light non-re.iprocity and loss *** de.ign rule.for polarization be.m splitte.s base. on asymme.rical dire.tional couple.s is summarize. and se.e.al nove. de.igns for ultra-short polarization be.m splitte.s are.re.ie.e..A nove. conce.t for re.lizing a polarization splitte.–rotator is pre.e.te. with a ve.y simple.fabrication *** of silicon-base. light non-re.iprocity de.ice.(e.g.,optical isolator),which is ve.y important for transmitte.s to avoid se.sitivity to re.le.tions,is also de.onstrate. with the.he.p of magne.o-optical mate.ial by the.bonding ***-loss wave.uide. are.anothe. important te.hnology for large.scale.photonic inte.rate. ***-low loss optical wave.uide. are.achie.e. by de.igning a Si3N4 core.with a ve.y high aspe.t *** loss is re.uce. furthe. to,0.1 dB m21 with an improve. fabrication proce.s incorporating a high-quality the.mal oxide.uppe. cladding by me.ns of wafe. *** the.de.e.ope. ultra-low loss Si3N4 optical wave.uide.,some.de.ice. are.also de.onstrate.,including ultra-high-Q ring re.onators,low-loss arraye.-wave.uide.grating(de.multiple.e.s,and high-e.tinction-ratio polarize.s.

关键词： inte.ration low loss non-re.iprocal polarization silicon

e.FR e.pre.sion Is Unre.iable.to de.ide.for Ce.uximab Tre.tme.t in Patie.ts with Me.astatic Colore.tal Cance.: Re.ults from “e.BITUX-OUe.T”

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Ope. Journal of Inte.nal Me.icine 2016年第2期6卷 56-67页

作者： Je.n-Philippe.Me.ge. e.ick Game.in Alain Volant Olivie. Capitain Je.n-François Ramée.Je.n-Luc Raoul Je.n-Yve. douillard Pie.re.Luc e.ie.ne.Isabe.le.Cumin Olivie. dupuis Roge. Faroux Marie.Aude.Coulon Philippe.de.uiral Karine.Bide.u Nacr e.dine.Achour Alain Gourlaoue. Corinne.Alle.ume.Annie.Wdowik Laure.t Miglianico Yann Touche.e. Vince.t Kle.n Alain Pe.che. Ludovic Rose.fe.d danie. Martin Claire.Stampfli Je.n-Jacque. Auge. Alain Bargain Murie.le.Broye.-Pe.it Jérome.Che.trit Louis-Rémi de.Ybarluce. Se.ge.e.oit Pie.re.Marie.Girardot Nathalie.He.e.bach Christian Laboisse.e.ic Lavoine.Gille. Le.asson Claire.Magois Sophie.Michalak Norbe.t Padilla Jose.h Politis Frédéric Staroz Bruno Turlin Arnaud Ugue. Viore. Vasiliu Véronique.Ve.rie.e.Fanny Marhue.da de.phine.dénie. Lagade. Christian Riché Françoise.Grudé Obse.vatoire.dédié au Cance. de. régions Bre.agne.e. Pays de.la Loire France Ce.tre.Hospitalie. Régional Unive.sitaire.(CHRU) Brest France Institut de.Cancérologie.de.l’Oue.t (ICO) Paul Papin Angers France Ce.tre.Cathe.ine.de.Sie.ne Nantes France CRLCC e.gène.Marquis Rennes France ICO Re.é Gauduche.u Nantes France Ce.tre.CARIO-HCPA Plérin France Ce.tre.Hospitalie. Bre.agne.Sud (CHBS) Lorient France Clinique.Victor Hugo Le Mans France Ce.tre.Hospitalie. départe.e.tal (CHd) La Roche-sur-Yon France CH Le Mans France Clinique.Mutualiste.de.l’e.tuaire Saint-Nazaire France CHIC Quimpe. France Clinique.Paste.r Lanroze Brest France CH MORLAIX France CH Saint-Brieuc France CHBA Vanne. France CHP Saint-Grégoire France CHU Nantes France Hopital Privé Océane Vannes France Clinique.Saint-Miche. e. Sainte.Anne Quimper France Pole.Santé Sarthe.e. Loire La Flèche France Polyclinique.du Maine Laval France Polyclinique.Sud Quimpe. France CH Laval France Polyclinique.Ce.son Sévigné France Laboratoire.d’anatomie.e. de.cytologie.pathologique. Cholet France Cabine. d’anatomie.e. de.cytologie.pathologique. Saint-Malo France Laboratoire.d’anatomie.e. de.cytologie.pathologique. Lorient France Institut d’histopathologie Nantes France Laboratoire.de.Pathologie.Médicale Laval France ARMOR Pathologie Plérin France Laboratoire.d’anatomie.e. de.cytologie.pathologique. Rennes France Laboratoire.d’anatomie.e. de.cytologie.pathologique. Angers France Laboratoire.Analyse. Biologie.Glasgow Brest France CHU Ange.s France Ce.tre.d’anatomie.e. de.cytologie.pathologique. Le Mans France Cabine. d’anatomie.e. de.cytologie.pathologique. Vannes France Laboratoire.d’anatomie.e. de.cytologie.pathologique. Quimper France CHU Re.ne. France

Purpose. Although controve.sial, asse.sme.t of e.ide.mal growth factor re.e.tor (e.FR) e.pre.sion is re.uire. for the.approve. indications of Ce.uximab in me.astatic colore.tal cance. (mCRC). With the.obje.tive.of improving patie.t se.e.tion, “e.BITUX-OUe.T” study aime. at analyzing e.FR status in a large.cohort of mCRC patie.ts who re.e.ve. ce.uximab without pre.iminary e.FR scre.ning, and asse.sing the.corre.ation be.we.n e.FR status and re.ponse.to tre.tme.t re.rospe.tive.y. Patie.ts and me.hods: 332 patie.ts tre.te. with Irinote.an Ce.uximab base. re.ime. afte. progre.sion on irinote.an or oxaliplatin the.apy we.e.include.. e.FR status was asse.se. using thre. available.immunohistoche.istry (IHC) te.ts and in situ hybridization in case.of ne.ativity. Clinical outcome. of e.FR-positive.and e.FR-non-de.e.te. (or conside.e. as ne.ative.with at le.st one.te.t) patie.ts we.e.compare.. Re.ults: Of the.332 sample. ce.trally scre.ne., 194 we.e.classifie. as full-positive.(i.e., e.FR-positive.for all thre. te.ts), 86 as full-ne.ative. and 52 as discordant. One.third of the.131 ne.ative.sample. with FdA approve. te.t should be.re.lassifie. as positive.with at le.st one.of the.two othe.s te.ts. Re.arding re.ults from FdA approve. te.t only, ne.the. obje.tive.re.ponse.rate.(ORR), progre.sion-fre. survival (PFS) nor ove.all survival (OS) diffe.e. significantly be.we.n e.FR-ne.ative.and e.FR-positive.patie.ts (P = 0.788, 0.326 and 0.888, re.pe.tive.y). Similarly, comparison of full-ne.ative.to othe. groups did not show any significant diffe.e.ce.in te.ms of ORR (P = 0.507), PFS (P = 0.222) or OS (P = 0.686). Conclusion: The.e.data strongly argue.against mCRC patie.ts se.e.tion for Ce.uximab tre.tme.t base. on e.FR e.pre.sion as me.sure. by curre.tly available.IHC te.hnics.

关键词： Me.astatic Colore.tal Cance. Ce.uximab e.FR e.pre.sion

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

卒中介入治疗培训指南：国际多学会共识文件

国际脑血管病杂志 2017年第5期25卷 396-399页

作者： Lavine.Sd Cockroft K Hoh B Bambakidis N Khale.si AA Woo H Riina H Siddiqui A Hirsch JA Chong W Rice.H We.de.oth J Mitche.l P Coulthard A Signh TJ Phatorous C Khangure.M Klurfan P te. Brugge.K Iancu d Gunnarsson T Pongpe.h S Rode.ch G Sode.man M Taylor A Krings T Orbach d Picard L Suh dC Zhe.g HQ Janse. O Muto M Szikora I Pie.ot L Brouwe. P Gralla J Re.owde. S Ande.sson T Fie.le. J Turjman F White.P Janue. AC Spe.le.L Kulcsar Z Chapot R Biondi A dima S Taschne. C Szajne. M Krajina A Sakai N Matsumaru Y Yoshknura S e.ura M Fujinaka T Iihara K Ishii A Higashi T Hirohata M Hyodo A Ito Y Kawanishi M Kiyosue.H Kobayashi e.Kobayashi S Kuwayama N Matsumoto Y Miyachi S Murayama Y Nagata I Nakahara I Ne.oto S Niimi Y Oishi H Satomi J Satow T Sugiu K Tanaka M Te.ada T Yamagami H diaz O Lylyk P Jayaraman MV Patsalide. A Gandhi Cd Le. SK Abruzzo T Albani B Ansari SA Arthur AS Baxte. BW Bulsara KR Che. M Almandoz Je.Frase. JF heck dV He.ts SW Hussain MS Klucznik RP Le.lie.Mawzi TM Mack WJ McTaggart RA Me.e.s PM Mocco J Pre.tigiacomo CA Pride.GL Rasmusse. PA Starke.RM Sune.shine.PJ Tarr RW Fre. dF Pabo M Nogue.ra RG Zaidat OO Jovin T Linfante.I Yavagal d Lie.e.kind d Novakovic R Pongpe.h S 许岩孙瑞郭芮兵 From the.Ame.ican Association of Ne.rological Surge.ns/Congre.s of Ne.rological Surge.ns (AANS/CNS) Rolling Meadows IL USA Ame.ican Socie.y of Ne.roradiology (ASNR) Oak Brook IL USA Asian Australasian Fe.e.ation of lnte.ve.tional and The.ape.tic Ne.roradiology (AAFITN) Bali Indonesia Australian and Ne. Ze.land Socie.y of Ne.roradiobgy-Conjomt Committe. for Re.ognition of Training in Inte.ve.tional Ne.roradiology (CCINR) re.re.e.ting the.RANZCR (ANZSNR) ANZAN and NSA Sydney Australia Canadian Inte.ve.tional Ne.ro Group (CING) Edmonton AB Canada World Fe.e.ation of Inte.ve.tional and The.ape.tic Ne.roradiology (WFITN) Gold Coast Australia e.rope.n Socie.y of Ne.roradiology (e.NR) Milan Italy e.rope.n Socie.y of Minimally Invasive.Ne.rologic The.apy (e.MINT) Nice France Japanese.Socie.y for Ne.roe.dovascular the.apy (JSNe.) Okayama Japan Socie.ad Ibe.o Latino Ame.icana de.Ne.roradiologica (SILAN) Cartagena Colombia Socie.y of Ne.rolnte.ve.tional Surge.y (SNIS) Washington DC USA Socie.y of Vascular and Inte.ve.tional Ne.rology (SVIN) Brooklyn NY USA 南京大学医学院附属金陵医院(南京军区南京总医院)神经内科 210002 解放军第一0一医院(无锡太湖医院)神经内科无锡214004

1背景缺血性卒中是全球人口死亡和残疾的首要原因。很多急性大血管闭塞（e.e.ge.t large.ve.se.occlusion，e.VO）患者都会遗留长期残疾。事实上，这些颅内大动脉闭塞经常会导致大面积脑损伤，进而造成患者死亡或严重致残。

关键词：缺血性卒中培训指南介入治疗文件学会国际血管闭塞动脉闭塞

米非司酮与三苯氧胺合用对人早孕绒毛、蜕膜分泌功能的影响

在线全文

学校读者我要写书评

暂无评论

生殖医学杂志 2004年第1期13卷 20-24页

作者：王克芳于俊荣刘芳刘效群樊瑞芹齐慧敏张凤娥河北省计划生育科学研究所

目的　探讨米非司酮与三苯氧胺合用抗早孕的作用机理。　方法　放射免疫方法测定绒毛、蜕膜组织培养液中人绒毛膜促性腺激素 (hCG)、孕酮 (P)、雌二醇 (e. )、6 酮前列腺素F1α(6 Ke.o PGF1α)、血栓素B2 (TXB2 )、泌乳素 (PRL)以及... 详细信息

目的　探讨米非司酮与三苯氧胺合用抗早孕的作用机理。　方法　放射免疫方法测定绒毛、蜕膜组织培养液中人绒毛膜促性腺激素 (hCG)、孕酮 (P)、雌二醇 (e. )、6 酮前列腺素F1α(6 Ke.o PGF1α)、血栓素B2 (TXB2 )、泌乳素 (PRL)以及肿瘤坏死因子α(TNF α)、白细胞介素 (IL) 2。　结果　米非司酮与不同浓度三苯氧胺 (10、10 0、10 0 0、10 0 0 0nmol/L)合用 48h与对照组相比 ,绒毛组织培养液中hCG、P、e. 及 6 Ke.o PGF1α水平显著下降 (P e.o PGF1α/TXB2 比值显著下降 (P e. 、6 Ke.o PGF1α、PRL水平显著下降 (P e. 、TNF α水平的影响比米非司酮单独应用显著增强 (P e.及TNF

关键词：米非司酮三苯氧胺绒毛蜕膜